Key Market Segments
By Type
-
Capping Agents
-
CleanCap Reagents
-
ARCA (Anti-Reverse Cap Analog)
-
Others
-
-
Nucleotides
-
Modified Nucleic Acids
-
N1-methylpseudouridine-triphosphate
-
5-Methylcytidine triphosphate (5mCTP)
-
Others
-
-
Natural Nucleic Acids
-
Adenine
-
Guanine
-
Cytosine
-
Uracil
-
-
-
Plasmid DNA
-
Enzymes
-
Polymerase
-
RNase Inhibitor
-
DNase
-
Others
-
-
Others
By Application
-
Vaccine Production
-
Therapeutics Production
-
Others
By End Use
-
Biopharmaceutical & Pharmaceutical Companies
-
CROs & CMOs
-
Academic & Research Institutes
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
-
Mexico
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Turkey
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Singapore
-
Australia
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g., Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Ans: Future trends include the increased adoption of personalized mRNA therapies, a rise in self-amplifying and circular RNA research, and the development of next-gen capping technologies to improve mRNA stability and translation.
Ans: North America, led by the U.S., dominates the market due to strong biotechnology infrastructure, government support, and major players headquartered in the region.
Ans: Key players include Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), TriLink BioTechnologies, New England Biolabs, Cytiva (Danaher), BioNTech, Moderna, GenScript, CureVac, and ST Pharm.
Ans: Growth is driven by the expanding application of mRNA technology in infectious disease vaccines, cancer therapeutics, and rare genetic disorders, along with heavy R&D investments, government funding, and the need for GMP-compliant raw materials such as nucleotides, capping agents, and enzymes.
Ans: The global mRNA synthesis raw materials market was valued at USD 1.70 billion in 2024 and is projected to reach USD 2.67 billion by 2032, growing at a CAGR of 5.81% from 2025 to 2032.